However, this may set the stage for failure. An investigational Alzheimer's disease drug called Dimebon is a case in point. A phase 2 trial of Dimebon reported significant improvements in ...
Medivation, Inc. (AMEX:MDV) today announced that its proprietary drug Dimebon(TM) met all five efficacy endpoints in a six-month randomized, double-blinded, placebo-controlled Phase 2 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback